Identification and characterisation of anti-IL-13 inhibitory single domain antibodies provides new insights into receptor selectivity and attractive opportunities for drug discovery.

Interleukin-13 (IL-13) is a cytokine involved in T-cell immune responses and is a well validated therapeutic target for the treatment of asthma, along with other allergic and inflammatory diseases. IL-13 signals through a ternary signalling complex formed with the receptors IL-13Rα1 and IL-4Rα. This complex is assembled by IL-13 initially binding IL-13Rα1, followed by association of the binary IL-13:IL-13Rα1 complex with IL-4Rα. The receptors are shared with IL-4, but IL-4 initially binds IL-4Rα. Here we report the identification and characterisation of a diverse panel of single-domain antibodies (VHHs) that bind to IL-13 (K

Informations de copyright

Copyright © 2023 Walker, Baravalle, Holyfield, Kalms, Wright, Seewooruthun, Muskett, Scott-Tucker, Merritt, Henry, Lawson, Hall, Prosser and Carr.

Déclaration de conflit d'intérêts

Authors JK, AS-T, AH, AL and CP are employees of UCB. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author's declare that this study received funding from the Antibody-Assisted Drug Discovery Consortium, which is a research partnership between the University of Leicester, LifeArc and UCB Biopharma. The funder was involved in the study design, collection, analysis, interpretation of data, the writing of this article, as well as the decision to submit it for publication.